Orion Corporation (OEC) To Commercialise Pembrolizumab Biosimilar in Europe

Orion Corporation (OEC) reported interim Phase III results showing that darolutamide, combined with ADT and RT, reduced the risk of metastasis or death by 58% in high-risk recurrent prostate cancer. The 4-year metastasis-free survival rate was 95% compared to 88%. Darolutamide is not yet approved for this use.

Orion (NYSE:OEC) reported Q2 updates on coatings and rubber segments. Specialty profitability was supported by pricing actions amid volatile oil-derived feedstock costs. Rubber adjusted EBITDA fell 61% YoY to $19 million. Orion said working capital added $4 million cash, capex fell to $25 million, and it retained full-year guidance assuming $80/bbl crude. Net debt was $961 million.

OEConnection (OEC) agreed to acquire UK fleet software platform Epyx and sister firms R2C Online and Business Gateway from Corpay Inc, backed by Francisco Partners. OEC plans to expand its European digital footprint in fleet servicing, maintenance and repair. Closing is expected this autumn, subject to regulatory approvals, with continuity for customers and partners.

Orion S.A. (OEC) filed an SEC Form 8-K — Results of Operations and Financial Condition. ORION S.A. Exhibit 99.1 Orion S.A. Reports Second Quarter Earnings HOUSTON— August 5, 2026—Orion S.A. (NYSE: OEC), a specialty chemical company, today reported Second Quarter 2026 Net sales of $501 million, a 7% improvement from the prior year, as 9% higher average year-over-year

Compass Therapeutics (NASDAQ:CMPX) published Phase 2/3 trial results for tovecimig in the Journal of Clinical Oncology. The study met primary and secondary endpoints, showing improved response rates and progression-free survival in advanced biliary tract cancer patients compared to paclitaxel alone. However, overall survival showed no significant difference, and adverse events were higher in the combination arm. Tovecimig remains investigational.

BeOne Medicines presented data at ESMO 2026 on three investigational cancer treatments. GPC3 x 4-1BB bispecific showed 36% ORR in liver cancer, PRMT5 inhibitor demonstrated 25.3% ORR in lung cancer, and CEA-targeting ADC achieved 56% ORR in high-CEA lung cancer. The company plans global trials for these treatments.